Cellular and humoral response to the fourth BNT162b2 mRNA COVID‐19 vaccine dose in patients with CLL
Sign Up to like & getrecommendations! Published in 2022 at "European Journal of Haematology"
DOI: 10.1111/ejh.13878
Abstract: We assessed the humoral and cellular response to the fourth BNT162b2 mRNA COVID‐19 vaccine dose in patients with CLL. A total of 67 patients with CLL and 85 age matched controls tested for serologic response… read more here.
Keywords: response; serologic response; patients cll; vaccine ... See more keywords
Abstract 3849: Frontline ibrutinib-based therapy enhances CART cell functions in patients with CLL: Analysis of the phase 3 randomized clinical trial ECOG-ACRIN E1912
Sign Up to like & getrecommendations! Published in 2024 at "Cancer Research"
DOI: 10.1158/1538-7445.am2024-3849
Abstract: Introduction: Despite the remarkable activity of CD19-directed chimeric antigen receptor T cell therapy (CART19), durable remissions remain low, especially in chronic lymphocytic leukemia (CLL). Ibrutinib is an oral irreversible inhibitor of Bruton’s tyrosine kinase and… read more here.
Keywords: treatment; ibrutinib; therapy; patients cll ... See more keywords
Deep and Sustained Responses in Patients with CLL Treated with Zanubrutinib or Zanubrutinib + Obinutuzumab in Phase 1/2 AU-003 and Phase 1b GA-101 Studies: A Report from the Zanubrutinib Extension Study
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-200363
Abstract: Introduction: The phase 1/2 AU-003 study (BGB-3111-AU-003; NCT02343120) evaluated zanubrutinib monotherapy in patients with various B-cell malignancies, including chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL). The phase 1b GA-101 study (NCT02569476) evaluated zanubrutinib in… read more here.
Keywords: patients cll; zanubrutinib; patients patients; cll sll ... See more keywords
COVID-19 in patients with CLL: how can we change the odds?
Sign Up to like & getrecommendations! Published in 2021 at "Blood"
DOI: 10.1182/blood.2021013286
Abstract: In this issue of Blood, Roeker et al report an updated analysis of an international, multicenter study on the outcomes of 374 patients with chronic lymphocytic leukemia (CLL) diagnosed with COVID-19. The current analysis evaluated… read more here.
Keywords: change odds; patients cll; cll change; covid patients ... See more keywords
Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination
Sign Up to like & getrecommendations! Published in 2021 at "Blood"
DOI: 10.1182/blood.2021014085
Abstract: Patients with chronic lymphocytic leukemia (CLL) have an impaired antibody response to COVID-19 vaccination. Here, we evaluated the antibody response to a third BNT162b2 mRNA vaccine in patients with CLL/small lymphocytic lymphoma (SLL) who failed… read more here.
Keywords: response; patients cll; vaccination; bnt162b2 mrna ... See more keywords
Patients with CLL have a lower risk of death from COVID-19 in the Omicron era
Sign Up to like & getrecommendations! Published in 2022 at "Blood"
DOI: 10.1182/blood.2022016147
Abstract: Previous studies have shown that patients with chronic lymphocytic leukemia (CLL) and corona virus disease 2019 (COVID-19) have high mortality rates. Infection with the omicron variant has been described as a milder disease course in… read more here.
Keywords: omicron; covid; patients cll; risk death ... See more keywords
Hybrid immunity in immunocompromised patients with CLL after SARS-CoV-2 infection followed by booster mRNA vaccination
Sign Up to like & getrecommendations! Published in 2022 at "Blood"
DOI: 10.1182/blood.2022016815
Abstract: Conflict of interest: COI declared see note COI notes: The authors declare no competing financial interests. MB is a consultant for Oxford Immunotech. AS is a consultant for Gritstone Bio, Flow Pharma, Arcturus Therapeutics, ImmunoScape,… read more here.
Keywords: cll sars; hybrid immunity; immunity immunocompromised; immunocompromised patients ... See more keywords
IgG testing, immunoglobulin replacement therapy, and infection outcomes in patients with CLL or NHL: real-world evidence
Sign Up to like & getrecommendations! Published in 2024 at "Blood Advances"
DOI: 10.1182/bloodadvances.2024013073
Abstract: Key Points • Hypogammaglobulinemia, infections/severe infections, and antimicrobial use were decreased in patients with CLL or NHL treated with IgRT.• Increased IgG testing was associated with increased hypogammaglobulinemia detection and lower rates of severe infection. read more here.
Keywords: cll nhl; patients cll; testing immunoglobulin; igg testing ... See more keywords
Zanubrutinib is well tolerated and effective in patients with CLL/SLL intolerant of ibrutinib/acalabrutinib: updated results
Sign Up to like & getrecommendations! Published in 2025 at "Blood Advances"
DOI: 10.1182/bloodadvances.2024015493
Abstract: Key Points • Only 40% of intolerance AEs in cohort 1 (ibrutinib intolerance) and 28% in cohort 2 (acalabrutinib intolerance) recurred with zanubrutinib.• After switching to zanubrutinib, 71% of patients in cohort 1 and 63%… read more here.
Keywords: tolerated effective; ibrutinib; effective patients; patients cll ... See more keywords
Risk of hypertension in patients with CLL/SLL who participated in ALPINE: A post hoc analysis.
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.16_suppl.e19016
Abstract: e19016 Background: Bruton tyrosine kinase (BTK) inhibitors are an important therapeutic option for patients with CLL/SLL. The first-generation BTK inhibitor, ibrutinib (ibru), is associated with an increased risk of hypertension. Zanubrutinib (zanu) is a next-generation… read more here.
Keywords: patients cll; anti htn; risk; cll sll ... See more keywords
Rare Germline ATM Variants Influence the Development of Chronic Lymphocytic Leukemia
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.22.00269
Abstract: PURPOSE Germline missense variants of unknown significance in cancer-related genes are increasingly being identified with the expanding use of next-generation sequencing. The ataxia telangiectasia–mutated (ATM) gene on chromosome 11 has more than 1,000 germline missense… read more here.
Keywords: germline atm; atm variants; patients cll; rare germline ... See more keywords